Advertisement

Reviews on Biomarker Studies in Psychiatric and Neurodegenerative Disorders

  • Paul C. Guest
Book

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1118)

Also part of the Proteomics, Metabolomics, Interactomics and Systems Biology book sub series (PMISB, volume 1118)

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Sho Takatori, Wenbo Wang, Akihiro Iguchi, Taisuke Tomita
    Pages 83-116
  3. Rafael Penadés, Nicolas Franck, Laura González-Vallespí, Marie Dekerle
    Pages 117-134
  4. Madia Lozupone, Maddalena La Montagna, Francesca D’Urso, Antonio Daniele, Antonio Greco, Davide Seripa et al.
    Pages 135-162
  5. Dong Ik Park, Christoph W. Turck
    Pages 163-173
  6. Gabriel R. Fries, Wei Zhang, Deborah Benevenuto, Joao Quevedo
    Pages 175-190
  7. Licia C. Silva-Costa, Pamela T. Carlson, Paul C. Guest, Valéria de Almeida, Daniel Martins-de-Souza
    Pages 191-206
  8. Liming Shen, Yuxi Zhao, Huajie Zhang, Chengyun Feng, Yan Gao, Danqing Zhao et al.
    Pages 207-233
  9. Joby Pulikkan, Agnisrota Mazumder, Tony Grace
    Pages 253-269
  10. Melissa Quintero, Danijela Stanisic, Guilherme Cruz, João G. M. Pontes, Tássia Brena Barroso Carneiro Costa, Ljubica Tasic
    Pages 271-293
  11. Back Matter
    Pages 319-328

About this book

Introduction

This book includes a series of reviews on general aspects of biomarker use in the study of psychiatric and neurodegenerative diseases and the development of medications involved in their treatment. It describes the pros and cons of the various approaches and covers the successes and failures in this research field. It is only by a thorough understanding of the shortcomings that progress can be made. The overall goal is to facilitate the understanding and treatment of these disorders, by providing a viable mechanism of catching up with other areas of modern medicine, such as diabetes and heart disease. Finally, it is anticipated that the development and application of valid biomarker tests and the leveraging of novel drug targets will help the fields of psychiatry on neurodegenerative disorders move into the area of personalized medicine where the right patients can receive the right medication at the right time for the best possible outcome.

Keywords

novel psychiatric medications diseases treatment improved outcomes drug development biomarker read-outs

Editors and affiliations

  • Paul C. Guest
    • 1
  1. 1.Department of Biochemistry and Tissue Biology, Institute of BiologyUniversity of Campinas (UNICAMP)CampinasBrazil

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-030-05542-4
  • Copyright Information Springer Nature Switzerland AG 2019
  • Publisher Name Springer, Cham
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-3-030-05541-7
  • Online ISBN 978-3-030-05542-4
  • Series Print ISSN 0065-2598
  • Series Online ISSN 2214-8019
  • Buy this book on publisher's site
Industry Sectors
Pharma
Biotechnology
Consumer Packaged Goods